Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B

被引：1
|
作者：
Zhang, Hao [1 ]
Zeng, Wenting [1 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 1, Dept Infect Dis, 151 Yanjiang Rd, Guangzhou 510120, Guangdong, Peoples R China
来源：
JAMA ONCOLOGY | 2019年 / 5卷 / 06期
关键词：
D O I：
10.1001/jamaoncol.2019.0641
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：914 / 915
页数：2
相关论文
共 50 条
  • [1] Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B Reply
    Choi, Jonggi
    Ko, Min Jung
    Lim, Young-Suk
    [J]. JAMA ONCOLOGY, 2019, 5 (06) : 916 - 917
  • [2] Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B
    Lee, Han Ah
    Seo, Yeon Seok
    Kim, Seung Up
    [J]. GASTROENTEROLOGY, 2020, 158 (08) : 2310 - 2311
  • [3] Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir?
    Kamal, Faisal
    Khan, Muhammad Ali
    [J]. GASTROENTEROLOGY, 2020, 158 (08) : 2311 - 2312
  • [4] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Lee, Hye Won
    Cho, Young Youn
    Lee, Hyein
    Lee, Jae Seung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Beom Kyung
    Park, Soo Young
    [J]. HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1083 - 1092
  • [5] Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee
    Young Youn Cho
    Hyein Lee
    Jae Seung Lee
    Seung Up Kim
    Jun Yong Park
    Do Young Kim
    Sang Hoon Ahn
    Beom Kyung Kim
    Soo Young Park
    [J]. Hepatology International, 2021, 15 : 1083 - 1092
  • [6] Lower risk of hepatocellular carcinoma among patients with chronic hepatitis B treated with tenofovir than entecavir
    Young-Suk Lim
    [J]. Cancer Biology & Medicine, 2018, (S1) : 19 - 20
  • [7] Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir? Reply
    Yip, Terry Cheuk-Fung
    Wong, Grace Lai-Hung
    [J]. GASTROENTEROLOGY, 2020, 158 (08) : 2312 - 2313
  • [8] Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B
    Choi, Won-Mook
    Choi, Jonggi
    Wong, Grace Lai-Hung
    Han, Seungbong
    Lim, Young-Suk
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (02): : 87 - 87
  • [9] Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B
    Yip, Terry C. F.
    Wong, Vincent Wai-Sun
    Tse, Yee-Kit
    Chan, Henry
    Wong, Grace Lai-Hung
    [J]. JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E128 - E128
  • [10] Tenofovir disoproxil fumarate is not associated with a lower risk of hepatocellular carcinoma compared to entecavir in patients with chronic hepatitis B
    Lee, Hye Won
    Kim, Seung Up
    [J]. HEPATOMA RESEARCH, 2022, 8
12345